{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:07:46Z","timestamp":1790554066319,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["200909"],"award-info":[{"award-number":["200909"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1023438"],"award-info":[{"award-number":["1023438"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1037304"],"award-info":[{"award-number":["1037304"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1132975"],"award-info":[{"award-number":["1132975"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1135820"],"award-info":[{"award-number":["1135820"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PA00P3_139723\/1"],"award-info":[{"award-number":["PA00P3_139723\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PBBSP3-125580"],"award-info":[{"award-number":["PBBSP3-125580"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ijpddr.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T12:20:14Z","timestamp":1624278014000},"page":"46-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia"],"prefix":"10.1016","volume":"17","author":[{"given":"Jutta","family":"Marfurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-8547","authenticated-orcid":false,"given":"Grennady","family":"Wirjanata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pak","family":"Prayoga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferryanto","family":"Chalfein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Leonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni F.","family":"Sebayang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwi","family":"Apriyanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maic A.E.M.","family":"Sihombing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leily","family":"Trianty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossarin","family":"Suwanarusk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Brockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Piera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-4890","authenticated-orcid":false,"given":"Irene","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rumaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-5068","authenticated-orcid":false,"given":"Barbara","family":"MacHunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Auburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Anstey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enny","family":"Kenangalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintis","family":"Noviyanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne R.","family":"Poespoprodjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2021.06.002_bib1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/infdis\/jix334","article-title":"Association of a novel mutation in the plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity","volume":"216","author":"Agrawal","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","article-title":"Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study","volume":"17","author":"Amato","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib5","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/s41467-018-04965-4","article-title":"Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics","volume":"9","author":"Auburn","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/infdis\/jiz016","article-title":"Genomic analysis of plasmodium vivax in southern Ethiopia reveals selective pressures in multiple parasite mechanisms","volume":"220","author":"Auburn","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41467-018-04104-z","article-title":"Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum","volume":"9","author":"Bopp","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib9","article-title":"UCT943, a next-generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria","volume":"62","author":"Brunschwig","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1590\/S0074-02761999000600017","article-title":"Antimalarial drug susceptibility testing of Plasmodium falciparum in Brazil using a radioisotope method","volume":"94","author":"Cerutti","year":"1999","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib11","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/AAC.00366-15","article-title":"Ex vivo drug susceptibility testing and molecular profiling of clinical plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance","volume":"59","author":"Chaorattanakawee","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00303-17","article-title":"A variant PfCRT isoform can contribute to plasmodium falciparum resistance to the first-line partner drug piperaquine","volume":"8","author":"Dhingra","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0166-6851(00)00201-2","article-title":"The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin","volume":"108","author":"Duraisingh","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12916-015-0539-5","article-title":"Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations","volume":"13","author":"Duru","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S1097-2765(05)00077-8","article-title":"Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance","volume":"6","author":"Fidock","year":"2000","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/345255a0","article-title":"Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum","volume":"345","author":"Foote","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/infdis\/jiu216","article-title":"Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi","volume":"210","author":"Frosch","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14787210.2017.1313703","article-title":"pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies","volume":"15","author":"Gil","year":"2017","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1473-3099(19)30392-5","article-title":"Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study","volume":"19","author":"Hamilton","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1128\/AAC.02306-12","article-title":"In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes","volume":"57","author":"Hao","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib22","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1365-2958.2004.04470.x","article-title":"pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum","volume":"55","author":"Hayward","year":"2005","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002815","article-title":"Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: a longitudinal surveillance study","volume":"16","author":"Kenangalem","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001772","article-title":"An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing","volume":"6","author":"Kerlin","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib25","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/AAC.02727-13","article-title":"KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission","volume":"58","author":"Kuhen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2307\/3280287","article-title":"Synchronization of Plasmodium falciparum erythrocytic stages in culture","volume":"65","author":"Lambros","year":"1979","journal-title":"J. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002138","article-title":"Characterization of novel antimalarial compound ACT-451840: preclinical assessment of activity and dose-efficacy modeling","volume":"13","author":"Le Bihan","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study","volume":"18","author":"Llanos-Cuentas","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpddr.2018.11.004","article-title":"Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine","volume":"9","author":"Loesbanluechai","year":"2019","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/1475-2875-9-375","article-title":"Implementation of a reference standard and proficiency testing programme by the world wide antimalarial resistance network (WWARN)","volume":"9","author":"Lourens","year":"2010","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1086\/589882","article-title":"Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in pvdhfr and pvmdr1","volume":"198","author":"Marfurt","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1128\/AAC.01220-10","article-title":"Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P","volume":"55","author":"Marfurt","year":"2011","journal-title":"vivax. Antimicrob.Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib33","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1128\/AAC.01375-10","article-title":"Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P","volume":"55","author":"Marfurt","year":"2011","journal-title":"vivax. Antimicrob.Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib34","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1128\/AAC.00283-12","article-title":"Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P","volume":"56","author":"Marfurt","year":"2012","journal-title":"vivax. Antimicrob.Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib35","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1128\/AAC.00283-12","article-title":"Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax","volume":"56","author":"Marfurt","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01538-19","article-title":"In vivo efficacy and pharmacokinetics of the 2-aminomethylphenol antimalarial JPC-3210 in the Aotus monkey-human malaria model","volume":"64","author":"McCallum","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ng.3189","article-title":"Genetic architecture of artemisinin-resistant Plasmodium falciparum","volume":"47","author":"Miotto","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib38","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1128\/AAC.00638-09","article-title":"In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1","volume":"53","author":"Mwai","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005029","article-title":"Quinolone-3-diarylethers: a new class of antimalarial drug","volume":"5","author":"Nilsen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJMc0900231","article-title":"Artemisinin-resistant malaria in Asia","volume":"361","author":"Noedl","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib41","doi-asserted-by":"crossref","first-page":"15159","DOI":"10.1038\/ncomms15159","article-title":"A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance","volume":"8","author":"O'Neill","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib42","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/gbe\/evx126","article-title":"Partner-drug resistance and population substructuring of artemisinin-resistant plasmodium falciparum in Cambodia","volume":"9","author":"Parobek","year":"2017","journal-title":"Genome Biol Evol"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib43","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ng.3599","article-title":"Genomic analysis of local variation and recent evolution in Plasmodium vivax","volume":"48","author":"Pearson","year":"2016","journal-title":"Nat. Genet."},{"issue":"42","key":"10.1016\/j.ijpddr.2021.06.002_bib45","article-title":"An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples","volume":"6","author":"Pearson","year":"2021","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib46","doi-asserted-by":"crossref","first-page":"11672","DOI":"10.1073\/pnas.1507142112","article-title":"Adaptive evolution of malaria parasites in French Guiana: reversal of chloroquine resistance by acquisition of a mutation in pfcrt","volume":"112","author":"Pelleau","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib47","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acsinfecdis.6b00144","article-title":"A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria","volume":"2","author":"Phillips","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4269\/ajtmh.17-0662","article-title":"Therapeutic response to dihydroartemisinin-piperaquine for P. Falciparum and P. Vivax nine years after its introduction in southern Papua, Indonesia","volume":"98","author":"Poespoprodjo","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib49","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.molmed.2015.10.004","article-title":"Challenges in antimalarial drug treatment for vivax malaria control","volume":"21","author":"Popovici","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib50","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1128\/AAC.00801-10","article-title":"In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax","volume":"54","author":"Price","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib51","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.trstmh.2006.06.008","article-title":"Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia","volume":"101","author":"Ratcliff","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/00034983.1973.11686885","article-title":"The removal of leucocytes from malaria infected blood","volume":"67","author":"Richards","year":"1973","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib53","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acs.biochem.0c00247","article-title":"Altered drug transport by plasmodium falciparum chloroquine resistance transporter isoforms harboring mutations associated with piperaquine resistance","volume":"59","author":"Riegel","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib54","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","article-title":"Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine","volume":"9","author":"Ross","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib55","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1128\/AAC.01334-07","article-title":"Determinants of in vitro drug susceptibility testing of Plasmodium vivax","volume":"52","author":"Russell","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib56","first-page":"219","article-title":"Expression and function of pvcrt-o, a Plasmodium vivax ortholog of pfcrt","volume":"vol. 150","author":"Sa","year":"2006"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib57","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMc1403007","article-title":"Dihydroartemisinin-piperaquine failure in Cambodia","volume":"371","author":"Saunders","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001089","article-title":"Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms","volume":"2","author":"Suwanarusk","year":"2007","journal-title":"PloS One"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12936-019-2949-x","article-title":"From marginal to essential: the golden thread between nutrient sensing, medium composition and Plasmodium vivax maturation in in vitro culture","volume":"18","author":"Thomson-Luque","year":"2019","journal-title":"Malar. J."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib60","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1126\/science.781840","article-title":"Human malaria parasites in continuous culture","volume":"193","author":"Trager","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib61","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/ncomms6521","article-title":"Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum","volume":"5","author":"Vaidya","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib62","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","article-title":"Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study","volume":"19","author":"van der Pluijm","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib63","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1038\/ncomms11553","article-title":"Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies","volume":"7","author":"Veiga","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib64","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1128\/AAC.01048-15","article-title":"Contrasting ex vivo efficacies of \"reversed chloroquine\" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates","volume":"59","author":"Wirjanata","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib65","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1128\/AAC.00874-15","article-title":"Potent ex vivo activity of naphthoquine and methylene blue against drug-resistant clinical isolates of plasmodium falciparum and plasmodium vivax","volume":"59","author":"Wirjanata","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ijpddr.2021.06.002_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00355-17","article-title":"Plasmodium falciparum and P. vivax demonstrate contrasting chloroquine resistance reversal phenotypes","volume":"61","author":"Wirjanata","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(02)00239-6","article-title":"Epidemiology of drug-resistant malaria","volume":"2","author":"Wongsrichanalai","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib69","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1128\/AAC.02350-12","article-title":"High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool","volume":"57","author":"Woodrow","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2021.06.002_bib70","series-title":"World Malaria Report 2019","year":"2019"},{"key":"10.1016\/j.ijpddr.2021.06.002_bib71","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acs.jmedchem.8b01799","article-title":"3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) derivatives with potent in vitro and in vivo antimalarial activity","volume":"62","author":"Xue","year":"2019","journal-title":"J. Med. Chem."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320721000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320721000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:52:28Z","timestamp":1761922348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320721000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":69,"alternative-id":["S2211320721000294"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2021.06.002","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}